477 related articles for article (PubMed ID: 31733094)
1. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
2. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Papaxoinis G; Fountzilas G; Rontogianni D; Dimopoulos MA; Pavlidis N; Tsatalas C; Pectasides D; Xiros N; Economopoulos T
Ann Oncol; 2008 Apr; 19(4):780-6. PubMed ID: 18156143
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
4. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
5. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
[TBL] [Abstract][Full Text] [Related]
6. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
7. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence.
Suh C; Huh J; Roh JL
Oral Oncol; 2008 Oct; 44(10):949-55. PubMed ID: 18234544
[TBL] [Abstract][Full Text] [Related]
8. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
9. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Zucca E; Conconi A; Pedrinis E; Cortelazzo S; Motta T; Gospodarowicz MK; Patterson BJ; Ferreri AJ; Ponzoni M; Devizzi L; Giardini R; Pinotti G; Capella C; Zinzani PL; Pileri S; López-Guillermo A; Campo E; Ambrosetti A; Baldini L; Cavalli F;
Blood; 2003 Apr; 101(7):2489-95. PubMed ID: 12456507
[TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristics and prognostic analysis of gastric mucosa-associated lymphoid tissue lymphoma of 103 cases].
Li XW; Xia B; Guo Q; Jin X; Yu Y; Zhao ZG; Wang XF; Wang YF; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):805-9. PubMed ID: 23384898
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Marginal Zone Lymphoma International Prognostic Index.
Hong J; Cho J; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2019 Feb; 98(2):457-464. PubMed ID: 30310985
[TBL] [Abstract][Full Text] [Related]
12. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients.
Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Makita S; Fukuhara S; Munakata W; Maruyama D; Kobayashi Y; Tobinai K
Br J Haematol; 2016 Sep; 174(6):923-31. PubMed ID: 27460179
[TBL] [Abstract][Full Text] [Related]
14. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
15. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical characteristics and prognostic factors of gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.
Xu X; Wang Z; Yu Y; Wang Y; Zhang L; Sun B; Da W; Zhang Y
J Gastroenterol Hepatol; 2014 Sep; 29(9):1678-84. PubMed ID: 24730769
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma].
Tian L; Zhang C; Liu W; Wang X; Zheng W; Xie Y; Lin N; Ying Z; Ping L; Deng L; Song Y; Zhu J
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):759-62. PubMed ID: 24844960
[TBL] [Abstract][Full Text] [Related]
20. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]